Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Core Scientific Inc (CORZ) Price & Performance

ACADIA Pharmaceuticals Inc.Trade

Core Scientific IncTrade

Price performance (Past 24H)

Key statistics

ACADIA Pharmaceuticals Inc. vs Core Scientific Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while Core Scientific Inc trades at $20.74 (market cap $6.35B). The key difference: Core Scientific Inc is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Core Scientific Inc nearer its low. Which is the better fit depends on your goals.

	ACAD	CORZ
Market Cap	$5.07B	$6.35B
Sector	Health	Technology
52-Week High	$29.41	$29.16
52-Week Low	$20.06	$13.55
Enterprise Value	$4.19B	$8.88B

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

No Aura AI signal available yet.

Core Scientific Inc

Core Scientific (CORZ) trades at $21.01, down 0.19% on the day, with technical indicators showing a bearish trend despite neutral oscillators. The company reported Q2 2026 revenue growth but missed earnings expectations with a significant net loss of -$1.4 billion for 2026. Recent news highlights a major partnership with AMD for AI infrastructure development, potentially driving future revenue growth through colocation services.

While analyst consensus remains strongly bullish with an 86% buy rating and $35.88 price target, fundamental risks include persistent negative profit margins and substantial cash burn. The AMD partnership offers significant upside potential, but investors must weigh execution risks against the company's current unprofitability and competitive pressures in the data center market.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ACAD

Immunic appoints Elena Ridloff to board ahead of key Phase 3 MS trial data and potential commercialization.PRNewsWire · 1 day agoBullish ACADIA Pharmaceuticals beats Q2 earnings and revenue estimates, raising 2026 revenue forecast and price target.Andrew Wynn · 1 day agoBullish View details →

CORZ

Neocloud stocks rise as NVIDIA-led $500B AI financing plan boosts data center buildout prospects24/7 Wall Street · 21 hours agoBullish CoreWeave Q2 earnings expected in line; Jefferies eyes founder stock sales as next catalyst, profit gains months awayProactive Investors · 22 hours agoBullish TeraWulf leads AI infrastructure stocks in 2026 with a 40.82% gain, driven by a major Anthropic lease deal.24/7 Wall Street · 1 day agoBullish View details →

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

About Core Scientific Inc

Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.